Plasma: source of life
Research & Development
Working at Grifols
Rest of the World
Grifols Announces Transfer of Management of Melville, New York Plasma Fractionation Facility to Kedrion
Today Grifols, S.A. (Grifols) announced that effective July 1, 2013, it will transfer management of the Melville
Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
Study results presented at annual meeting of American Thoracic Society (ATS)
Grifols officially inaugurates new immunoglobulin plant in the United States
IVIGs are the most important and most widely consumed plasma derived protein therapies
We are a solid company with an international dimension.
Instituto Grifols and Grifols Biologicals
We contribute to improving people’s health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.
Victor Grifols Foundation
Environment Day Contest 2013
Environmental Report 2011
Grifols is holding the fifth edition of the Martin Villar Awards for Research in Haemostasis.
© Barcelona 2011 Grifols S.A.
The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products available in your country, please select your country from the list at the top of the page.